Please use this identifier to cite or link to this item:
|Title:||CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine||Authors:||Suetani, S.
McGrath, J. J.
|Issue Date:||2018||Source:||BMJ open Mar 2 8, (3), 2018, p. e021000||Pages:||e021000||Journal Title:||BMJ open||Journal:||BMJ Open||Abstract:||INTRODUCTION: Clozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM). Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation. METHODS AND ANALYSIS: A 24-week double-blind placebo-controlled trial of concomitant prescription of metformin at clozapine commencement. Eighty-six people being commenced on clozapine will be randomised to placebo or metformin (variable dose, up to 2 g/day). The primary outcome is comparative end point body weight, between the placebo and metformin groups. Secondary outcomes are comparative rates of conversion to T2DM, alteration of metabolic syndrome parameters, proportion gaining >5% body weight and changes in diet and appetite. We will additionally examine biomarkers associated with change in weight among trial participants. ETHICS AND DISSEMINATION: Ethics approval was granted by the Metro South Human Research Ethics Committee HREC/17/QPAH/538-SSA/17/QPAH/565. We plan to submit a manuscript of the results to a peer-reviewed journal, and present results at conferences, consumer forums and hospital grand rounds. TRIAL REGISTRATION NUMBER: ACTRN12617001547336; Pre-results.2044-6055Siskind, Dan
McGrath, John J
Research Support, Non-U.S. Gov't
BMJ Open. 2018 Mar 2;8(3):e021000. doi: 10.1136/bmjopen-2017-021000.
|Keywords:||*clozapine*diabetes;*metabolic syndrome;*obesity;*schizophrenia;AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk and Sanofi and;has participated on advisory panels for MSD and Novo Nordisk.||Type:||Article|
|Appears in Collections:||Publications|
Files in This Item:
|Siskind 2018.pdf||615.43 kB||Adobe PDF|
checked on Dec 7, 2019
checked on Dec 7, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.